TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25348346

Group type: EXPERIMENTAL
Intervention: Integrated care including treatment as usual plus a psychoeducational intervention (14 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (pharmacotherapy and regular sessions with psychiatrist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online training of psychotherapists
Number of subjects: 0
Study: 22180331

Group type: EXPERIMENTAL
Intervention: High negative pressure suction (HNPS) at -600 mmHg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low negative pressure suction (LNPS) at -125 mmHg
Number of subjects: 21
Study: 19399700

Group type: EXPERIMENTAL
Intervention: ICD-10-Symptom-Rating (ISR)
Number of subjects: 1057
Study: 17631702

Group type: EXPERIMENTAL
Intervention: rhGH treatment (10 U hypodermically daily for 10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 15853822

Group type: EXPERIMENTAL
Intervention: Intraduodenal (ID) glucose (300 kcal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intragastric (IG) glucose (300 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intragastric water (control)
Number of subjects: 12
Study: 14520844

Group type: EXPERIMENTAL
Intervention: pumpan
Number of subjects: 30
Study: 12774460

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication
Number of subjects: 17
Study: 9125281

Group type: EXPERIMENTAL
Intervention: 0.1% DMM (dimethindene maleate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.1% azelastine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.025% DMM
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1995083

Group type: EXPERIMENTAL
Intervention: Bright morning light (6:00 to 8:00 AM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bright evening light (7:00 to 9:00 PM)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bright morning light
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hypersomnia
Number of subjects: 19
Study: 6638143

Group type: EXPERIMENTAL
Intervention: Upright short‐sitting in an adapted wheelchair
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Semiprone on an inclined prone positioner
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control variable - level of independent mobility
Number of subjects: 26
Study: 30509850

Group type: EXPERIMENTAL
Intervention: SIS plus standard care (n = 67)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care alone (n = 63)
Number of subjects: 130
Study: 29316154

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (n=71)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (n=72)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lipid profile and cytokines
Number of subjects: 160
Study: 27590259

Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas®, BAY 63‐2521) administered over 26 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas®, BAY 63‐2521)
Number of subjects: 0
Study: 25315937

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 36
Study: 22361121

Group type: EXPERIMENTAL
Intervention: Gaviscon® (4 × 10 mL/day)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Omeprazole (20 mg/day)
Number of subjects: 278
Study: 19710677

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Spoon feeding
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Spoon feeding in hospital
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Spoon feeding at home
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Transition to breast feeding (Trial I)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Transition to breast feeding (Trial II)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Duration of hospital stay (Trial II)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Neonatal morbidity
Number of subjects: 144
Study: 17644123

Group type: EXPERIMENTAL
Intervention: Local therapy for select patients with increasing PSA values below 1.0 ng/ml and lower Gleason score neoplasms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restaging to determine metastatic disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current knowledge about biochemical relapse management strategies.
Number of subjects: 0
Study: 16246659

Group type: EXPERIMENTAL
Intervention: Intracervical levonorgestrel-releasing device (20 microg/day)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Intrauterine levonorgestrel-releasing device (20 microg/day)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Both groups (cervical and uterine)
Number of subjects: 298
Study: 12384633

Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial intravascular ultrasound and angiography
Number of subjects: 0
Study: 9428214

Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 165

Group type: COMPARATOR
Intervention: Nonteratogenic controls
Number of subjects: 165
Study: 7542675

Group type: EXPERIMENTAL
Intervention: Loratadine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2677386

Group type: EXPERIMENTAL
Intervention: Modified relaxation training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (told stories)
Number of subjects: 12
Study: 347569

Group type: EXPERIMENTAL
Intervention: Valproate with reduced phenobarbital dose (by about 40%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Phenobarbital alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Valproate and Phenobarbital
Number of subjects: 17
Study: 31916678

Group type: EXPERIMENTAL
Intervention: Chicken meat consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef meat consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chicken consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General meat intake assessment
Number of subjects: 0
Study: 30964527

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard-dose vitamin D3
Number of subjects: 139
Study: 28073958

Group type: EXPERIMENTAL
Intervention: Exposure to rudeness (rude comments from the patient's mother)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (neutral comments)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exposure to rudeness with cognitive bias modification (CBM) intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exposure to rudeness with narrative intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exposure to rudeness
Number of subjects: 39
Study: 26172084

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla-300)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/ml (Gla-100)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 629
Study: 23238658

Group type: EXPERIMENTAL
Intervention: Mild retinopathy
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: Severe retinopathy
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: Progression of diabetic retinopathy at 4 years
Number of subjects: 3433
Study: 21317434

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 82
Study: 19966913

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1656
Study: 16440531

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14687141

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol
Number of subjects: 2357
Study: 11174775

Group type: EXPERIMENTAL
Intervention: Claudication patients
Number of subjects: 2777
Study: 9322456

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cm H2O
Number of subjects: 9

Group type: COMPARATOR
Intervention: No PSV (Control)
Number of subjects: 9
Study: 8187975

Group type: EXPERIMENTAL
Intervention: Men with adenoma
Number of subjects: 39

Group type: COMPARATOR
Intervention: Men without adenoma
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Women with adenoma
Number of subjects: 39

Group type: COMPARATOR
Intervention: Women without adenoma
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 39
Study: 2444307

Group type: EXPERIMENTAL
Intervention: Bromocriptine 5 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg and 5 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31296249

Group type: EXPERIMENTAL
Intervention: 3 sessions per week of acupuncture for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 session per week of acupuncture for 8 weeks
Number of subjects: 60
Study: 28414488

Group type: EXPERIMENTAL
Intervention: Treatment for Self-Injurious Behaviors (T-SIB); n = 15
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual; n = 18
Number of subjects: 33
Study: 25902141

Group type: EXPERIMENTAL
Intervention: Updating group
Number of subjects: 115

Group type: COMPARATOR
Intervention: Exposure group
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 23369948

Group type: EXPERIMENTAL
Intervention: Cardiac hypothermia (myocardial temperature between 18-28 °C during ACC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cardiac normothermia (myocardial temperature over 34 °C during ACC)
Number of subjects: 40
Study: 21518693

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: Trans-fatty acid 18:1 (TFA 18:1)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: Trans-fatty acid 18:2 (TFA 18:2)
Number of subjects: 3451
Study: 19092613

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 102

Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 102
Study: 16418308

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) 850 mg/m2 intravenously every 4 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination subcutaneously at 2-week intervals for first five vaccinations, then every 4 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) chemotherapy
Number of subjects: 108
Study: 15105682

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (initiated before 72 hours after injury)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Late enteral feeding (initiated more than 120 hours after injury)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 17

Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 17
Study: 11688002

Group type: EXPERIMENTAL
Intervention: Aprotinin (6 x 10(6) KIU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study: 9055050

Group type: EXPERIMENTAL
Intervention: Adjudication by five independent adjudicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjudication by two or three independent adjudicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjudication by a single independent adjudicator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjudication process
Number of subjects: 0
Study: 7955182

Group type: EXPERIMENTAL
Intervention: Heparin plus antithrombin III (250 U heparin + 25 U antithrombin III per minute)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Heparin alone (250 U heparin per minute)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Heparin plus antithrombin III
Number of subjects: 615

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 615
Study: 3631471

Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: nalbuphine 5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: morphine 5 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 29921538

Group type: EXPERIMENTAL
Intervention: Cooperative learning
Number of subjects: 1460
Study: 27013513

Group type: EXPERIMENTAL
Intervention: PrEP (tenofovir-emtricitabine)
Number of subjects: 515
Study: 24065784

Group type: EXPERIMENTAL
Intervention: Pharmacist-directed seamless care program
Number of subjects: 0
Study: 23772532

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose remifentanil (0.02, 0.05, and 0.07 microg x kg ‐1 x hr‐1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose remifentanil
Number of subjects: 52
Study: 20202912

Group type: EXPERIMENTAL
Intervention: Intensive support
Number of subjects: 442

Group type: COMPARATOR
Intervention: Basic support
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 442
Study: 18979547

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, i.v. infusion for 3 consecutive weeks followed by 1-week rest)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no anticancer intervention)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 49
Study: 12195873

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg b.i.d.
Number of subjects: 954

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg b.i.d.
Number of subjects: 954
Study: 9702844

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8040170

Group type: EXPERIMENTAL
Intervention: Balanced analgesia group comprising preincisional block and premedication with opiate and NSAID (Group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preincisional block, opiate premedication, and premedication with NSAID's
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 1 patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Balanced analgesic regime with NSAID and continuous extrapleural intercostal nerve block
Number of subjects: 56
Study: 2742785

Group type: EXPERIMENTAL
Intervention: Initial cessation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Long-term abstinence
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Predictors of initial cessation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Predictors of long-term abstinence
Number of subjects: 402
Study: 4422902

Group type: EXPERIMENTAL
Intervention: Coarse bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine bran
Number of subjects: 0
Study: 30705243

Group type: EXPERIMENTAL
Intervention: Short email with protocol attached
Number of subjects: 76

Group type: COMPARATOR
Intervention: Long email without protocol attached
Number of subjects: 76
Study: 28737593

Group type: EXPERIMENTAL
Intervention: Educational intervention about the harms of smoking regarding fracture healing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 25942457

Group type: EXPERIMENTAL
Intervention: Sex with someone other than primary partner and <100% condom use
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Abstinence from sex in the previous month
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Sex with both primary and other partners and <100% condom use in nonpolygamous marriages
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: At least one 72-hour gap in adherence
Number of subjects: 1147
Study: 23204039

Group type: EXPERIMENTAL
Intervention: adalimumab subcutaneously for 4 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: control (topical therapies or phototherapy)
Number of subjects: 30
Study: 21752481

Group type: EXPERIMENTAL
Intervention: 30Gy in 5 fractions (5.0Gy per fraction)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: 28.5Gy in 5 fractions (5.7Gy per fraction)
Number of subjects: 915

Group type: COMPARATOR
Intervention: 50Gy in 25 fractions (2.0Gy per fraction)
Number of subjects: 915
Study: 19729522

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 16974199

Group type: EXPERIMENTAL
Intervention: 50 mg/kg GHB (Xyrem)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GHB plus ethanol
Number of subjects: 16
Study: 15339684

Group type: EXPERIMENTAL
Intervention: rHuEpo (50 UI/kg three times a week for 4 weeks; 20 UI/kg three times a week for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10931603

Group type: EXPERIMENTAL
Intervention: Direct stenting without predilatation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional stenting with predilatation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 9051093

Group type: EXPERIMENTAL
Intervention: G‐CSF, 300 micrograms subcutaneously
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G‐CSF, 600 micrograms subcutaneously
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G‐CSF, 300 micrograms subcutaneously plus dexamethasone, 8 mg orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: G‐CSF, 600 micrograms subcutaneously plus dexamethasone, 8 mg orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexamethasone (any dose)
Number of subjects: 5
Study: 8312118

Group type: EXPERIMENTAL
Intervention: Intraperitoneal P32
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (BEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended field irradiation with weekly cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy prior to pelvic radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0
Study: 31549519

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise (MET)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 64
Study: 28679168

Group type: EXPERIMENTAL
Intervention: High Heart Failure Risk Status (HFRS)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Low or medium Heart Failure Risk Status (HFRS)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Automatic remote monitoring alerts
Number of subjects: 722
Study: 25991608

Group type: EXPERIMENTAL
Intervention: snus
Number of subjects: 391

Group type: COMPARATOR
Intervention: nicotine gum
Number of subjects: 391
Study: 24806836

Group type: EXPERIMENTAL
Intervention: CHO-rich diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fat-rich diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 19
Study: 21930719

Group type: EXPERIMENTAL
Intervention: Improved antihypertensive treatment
Number of subjects: 3534
Study: 21179729

Group type: EXPERIMENTAL
Intervention: Shengxue Mixture (SXM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 40
Study: 18426345

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Cefotetan (2 g)
Number of subjects: 1002
Study: 16551150

Group type: EXPERIMENTAL
Intervention: Positive therapeutic relationship early in treatment
Number of subjects: 0
Study: 14519829

Group type: EXPERIMENTAL
Intervention: Black tea (5 servings/day)
Number of subjects: 15
Study: 10910858

Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% lidocaine (1% lidocaine in sterile distilled water at a ratio of 1:3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neat 1% lidocaine
Number of subjects: 0
Study: 8694205

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study: 1388091

Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg TID (900 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Naproxen 500 mg BID (1000 mg/day)
Number of subjects: 99
Study: 3986073

Group type: EXPERIMENTAL
Intervention: Finapres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accutorr
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-Arterial-Line
Number of subjects: 0
Study: 31724891

Group type: EXPERIMENTAL
Intervention: Deep learning method with deeper breathing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deep learning method with talking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deep learning method with arm movement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual auscultatory method
Number of subjects: 40
Study: 30131256

Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN) 1500–2000 mg/d
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3414

Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN)
Number of subjects: 3414
Study: 26597421

Group type: EXPERIMENTAL
Intervention: Multi-component hospital pharmacist-led behavioural counselling and/or pharmacotherapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (routine care provided by hospitals)
Number of subjects: 600
Study: 23860945

Group type: EXPERIMENTAL
Intervention: Singing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rhythmic speaking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Speaking
Number of subjects: 60
Study: 22980576

Group type: EXPERIMENTAL
Intervention: AFO/footwear combination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 10
Study: 20438786

Group type: EXPERIMENTAL
Intervention: 1,25(OH)(2)D(3) treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 32